See more : H.U. Group Holdings, Inc. (4544.T) Income Statement Analysis – Financial Results
Complete financial analysis of PlexBio Co., Ltd. (6572.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PlexBio Co., Ltd., a leading company in the Healthcare industry within the Healthcare sector.
- Garrett Motion Inc. (GTX) Income Statement Analysis – Financial Results
- BeiGene, Ltd. (6160.HK) Income Statement Analysis – Financial Results
- China Vered Financial Holding Corporation Limited (0245.HK) Income Statement Analysis – Financial Results
- Shanghai Smart Control Co., Ltd. (001266.SZ) Income Statement Analysis – Financial Results
- HTC Corporation (2498.TW) Income Statement Analysis – Financial Results
PlexBio Co., Ltd. (6572.TWO)
About PlexBio Co., Ltd.
PlexBio Co., Ltd. develops and manufactures in vitro diagnostic reagents for molecular biology and immunology projects. It offers workflow navigation services; automated sample preparation extraction kits; IntelliPlex platform that is designed for pCode technology with for sample-to-answer multiplexing assays; oncology kits for lung cancer and mutation detection, as well as rearrangements; IntelliPlex SARS-CoV-2 detection test kits/flu kits and IntelliPlex SARS-CoV-2 variant analysis kits; and pCode coupling buffer sets. PlexBio Co., Ltd. was founded in 2009 and is based in Taipei, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 167.18M | 191.19M | 124.94M | 101.35M | 0.00 |
| Cost of Revenue | 104.71M | 132.19M | 86.38M | 59.67M | 0.00 |
| Gross Profit | 62.47M | 59.00M | 38.56M | 41.68M | 0.00 |
| Gross Profit Ratio | 37.37% | 30.86% | 30.86% | 41.13% | 0.00% |
| Research & Development | 62.97M | 72.61M | 113.31M | 113.37M | 0.00 |
| General & Administrative | 38.66M | 37.39M | 40.51M | 44.22M | 0.00 |
| Selling & Marketing | 24.99M | 15.93M | 20.00M | 32.40M | 0.00 |
| SG&A | 63.65M | 53.32M | 60.51M | 76.62M | 0.00 |
| Other Expenses | 0.00 | 10.96M | 1.59M | 3.27M | 0.00 |
| Operating Expenses | 126.62M | 125.93M | 173.82M | 189.99M | 0.00 |
| Cost & Expenses | 231.33M | 258.12M | 260.20M | 249.66M | 0.00 |
| Interest Income | 8.27M | 3.01M | 2.31M | 4.21M | 1.98M |
| Interest Expense | 263.00K | 167.00K | 226.00K | 234.00K | 386.00K |
| Depreciation & Amortization | 17.99M | 20.08M | 24.55M | 25.30M | 0.00 |
| EBITDA | -40.28M | -32.89M | -106.81M | -115.54M | -148.63M |
| EBITDA Ratio | -24.09% | -17.20% | -85.49% | -114.00% | 0.00% |
| Operating Income | -64.15M | -52.97M | -131.36M | -140.84M | 0.00 |
| Operating Income Ratio | -38.37% | -27.71% | -105.14% | -138.96% | 0.00% |
| Total Other Income/Expenses | 5.62M | 13.80M | 3.67M | 7.24M | -30.00K |
| Income Before Tax | -58.53M | -53.14M | -131.59M | -141.07M | 0.00 |
| Income Before Tax Ratio | -35.01% | -27.79% | -105.32% | -139.19% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -58.53M | -53.14M | -131.59M | -141.07M | 0.00 |
| Net Income Ratio | -35.01% | -27.79% | -105.32% | -139.19% | 0.00% |
| EPS | -0.56 | -0.51 | -1.27 | -1.37 | -2.32 |
| EPS Diluted | -0.56 | -0.51 | -1.27 | -1.37 | -2.32 |
| Weighted Avg Shares Out | 103.65M | 103.65M | 103.54M | 103.01M | 79.86M |
| Weighted Avg Shares Out (Dil) | 104.52M | 103.65M | 103.54M | 103.01M | 79.86M |
Source: https://incomestatements.info
Category: Stock Reports